# Apimeds Pharmaceuticals US, Inc. (APUS) — merger/definitive [pending]
Source: sec.gov · situation sit_cbc1f61152b9ae0e62f5 · public 4654560081359876388 · retrieved 2026-08-20T12:58:30.492Z

## Overview
Apimeds US is not associated with the market, sale and revenues generated from Apitoxin in South Korea, and Apitoxin has not yet been approved by the FDA for any indication.

As previously announced, the Company entered into that certain Agreement and Plan of Merger, signed and closed on December 1, 2025 (the " Merger Agreement "), with Apimeds Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company, MindWave Innovations Inc., a Delaware corporation (" MindWave "), and other parties signatory thereto.

## Key dates
- Announced 2026-04-09

## Timeline
- 2026-04-09 · 425 (0001213900-26-042030): 425 - Apimeds Pharmaceuticals US, Inc. — *Apimeds US is not associated with the market, sale and revenues generated from Apitoxin in South Korea, and Apitoxin has not yet been approved by the FDA for any indication.* As previously announced, the Company entered into that certain Agreement and Plan of Merger, signed and closed on December 1, 2025 (the " Merger Agreement "), with Apimeds Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company, MindWave Innovations Inc., a Delaware corporation (" MindWave "), and other parties signatory thereto.
  https://www.sec.gov/Archives/edgar/data/1894525/0001213900-26-042030.txt

## Citations
- 0001213900-26-042030 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000121390026042030